US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Polyrizon Ltd.

10.30

-0.1900-1.81%

Post-market: 10.00-0.3000-2.91%16:30 EDT

Volume:23.20K

Turnover:241.08K

Market Cap:21.46M

PE:-2.10

High:10.86

Open:10.86

Low:10.25

Close:10.49

52wk High:18.20

52wk Low:2.88

Shares:2.08M

Float Shares:1.65M

Volume Ratio:0.20

T/O Rate:1.41%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.9017

ROE:-25.38%

ROA:-28.95%

PB:1.02

PE(LYR):- -

Loading ...

Overview Company News Filings

Polyrizon director Carmel Liron disposes of shares worth $0.0011 million

Polyrizon CEO Tomer Izraeli disposes of 3,900 shares worth $0.04 million

Polyrizon completes FDA pre-submission meeting for NASARIX; submits FDA Pre-RFD for PL-16 viral blocker

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Polyrizon FY2025 operating loss widened 380% to $6.25 million; revenue was no revenue

Polyrizon signs MOU to buy up to 20% of Colugo for up to USD 6 million

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced Evtol Drones for Defense and Urban Air Mobility Applications

THOMSON REUTERS

Polyrizon Ltd. Director Liat Sidi Files Initial Beneficial Ownership Statement

Polyrizon Ltd. Chief Science Officer Eyal S. Ron filed initial beneficial ownership statement

Polyrizon Ltd. Director Yehonatan Zalman Vinokur Files Initial Beneficial Ownership Statement

Polyrizon Ltd. files Form 3 initial beneficial ownership statement for Director Carmel Liron

Polyrizon Ltd. files initial beneficial ownership statement for CTO Tidhar Turgeman

Polyrizon Ltd. director Oz Adler files initial beneficial ownership statement

Polyrizon Ltd. files Form 3 beneficial ownership statement for CEO Tomer Izraeli

Polyrizon Ltd. CFO Nir BenYosef files initial beneficial ownership statement

Polyrizon signs agreement with research organization for clinical development

Polyrizon signs agreement with global preclinical CRO for ISO 10993 biocompatibility studies

Polyrizon Signs an Agreement With Leading Global Preclinical Cro as Part of Clinical Development Program

THOMSON REUTERS

Polyrizon Produces GMP Clinical Trial Material Batch With Eurofins CDMO AmatsiAquitaine

Polyrizon Announces Gmp Manufacturing of Clinical Trial Material (Ctm) With Eurofins CDMO Amatsiaquitaine S.a.s for Planned U.S. Clinical Study

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PLRZ/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":10.3,"timestamp":1787342400000,"preClose":10.49,"halted":0,"volume":23198,"hourTrading":{"tag":"盘后","latestPrice":10,"preClose":10.3,"latestTime":"16:30 EDT","volume":2024,"amount":20442.55,"timestamp":1787344206189,"change":-0.3,"changeRate":-0.029126,"amplitude":0.029126},"delay":0,"changeRate":-0.01811248808388937,"floatShares":1648899,"shares":2083979,"eps":-4.901672,"marketStatus":"Market Closed","change":-0.19,"latestTime":"08-21 16:00:00 EDT","open":10.86,"high":10.86,"low":10.252,"amount":241082.77921,"amplitude":0.05796,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.901672,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":10.49,"preHourTrading":{"tag":"盘前","latestPrice":10.98,"preClose":10.49,"latestTime":"08:45 EDT","volume":10,"amount":109.80000000000001,"timestamp":1787316350024,"change":0.49,"changeRate":0.046711,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":10,"preClose":10.3,"latestTime":"16:30 EDT","volume":2024,"amount":20442.55,"timestamp":1787344206189,"change":-0.3,"changeRate":-0.029126,"amplitude":0.029126},"volumeRatio":0.19734782522234245},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":1648899,"roa":"-28.95%","roe":"-25.38%","lyrEps":0,"volumeRatio":0.19734782522234245,"shares":2083979,"dividePrice":0,"high":10.86,"amplitude":0.05796,"preClose":10.49,"low":10.252,"week52Low":2.88,"pbRate":"1.02","week52High":18.2,"institutionHeld":0,"latestPrice":10.3,"eps":-4.901672,"divideRate":0,"volume":23198,"delay":0,"ttmEps":-4.901672,"open":10.86,"prevYearClose":8.49,"prevWeekClose":10.98,"prevMonthClose":11.25,"prevQuarterClose":12.52,"fiveDayClose":10.98,"twentyDayClose":14.68,"sixtyDayClose":16.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-28","symbol":"PLRZ","defaultRemindTime":1764340200000,"type":"split","dateTimestamp":1764306000000,"forFactor":6,"toFactor":1,"ratio":6},{"market":"US","date":"2025-05-27","symbol":"PLRZ","defaultRemindTime":1748352600000,"type":"split","dateTimestamp":1748318400000,"forFactor":250,"toFactor":1,"ratio":250}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2026-08-21","current":-2.101324,"percent":0.592018,"low":-29.515607,"twenty":-11.696628,"median":-6.632,"eighty":-3.047315,"high":-0.011381,"avg":-7.999682,"sd":6.110678,"marketCap":19635685},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-11","current":-0.980061,"twenty":-5.4398,"median":-3.702849,"eighty":-2.640357,"marketCap":1514194},{"date":"2025-04-17","current":-0.985491,"twenty":-5.322255,"median":-3.619184,"eighty":-1.846098,"marketCap":1522583},{"date":"2025-04-25","current":-0.947483,"twenty":-5.174691,"median":-3.5049,"eighty":-1.520317,"marketCap":1463861},{"date":"2025-05-02","current":-0.687943,"twenty":-5.159991,"median":-3.434137,"eighty":-1.353625,"marketCap":1062872},{"date":"2025-05-09","current":-2.602277,"twenty":-5.095085,"median":-3.375088,"eighty":-1.466019,"marketCap":4020518},{"date":"2025-05-16","current":-0.039201,"twenty":-5.02132,"median":-3.354145,"eighty":-1.299871,"marketCap":60566},{"date":"2025-05-23","current":-0.018499,"twenty":-5.006408,"median":-3.310183,"eighty":-1.057434,"marketCap":28581},{"date":"2025-05-30","current":-0.022023,"twenty":-4.999463,"median":-3.245278,"eighty":-1.021327,"marketCap":34025},{"date":"2025-06-06","current":-0.014912,"twenty":-4.937359,"median":-3.214447,"eighty":-0.978975,"marketCap":23039},{"date":"2025-06-13","current":-0.018851,"twenty":-4.922267,"median":-3.183486,"eighty":-0.945854,"marketCap":29125},{"date":"2025-06-20","current":-0.013358,"twenty":-4.871782,"median":-3.155299,"eighty":-0.895899,"marketCap":20638},{"date":"2025-06-27","current":-2.431375,"twenty":-4.817057,"median":-3.116926,"eighty":-0.895899,"marketCap":3756474},{"date":"2025-07-03","current":-2.428961,"twenty":-4.79003,"median":-3.054617,"eighty":-0.90676,"marketCap":3752744},{"date":"2025-07-11","current":-2.469311,"twenty":-4.75787,"median":-3.036282,"eighty":-0.929565,"marketCap":3815085},{"date":"2025-07-18","current":-3.343916,"twenty":-4.728069,"median":-3.039365,"eighty":-0.942596,"marketCap":5166350},{"date":"2025-07-25","current":-4.793774,"twenty":-4.784488,"median":-3.066787,"eighty":-0.954976,"marketCap":7406381},{"date":"2025-08-01","current":-9.134632,"twenty":-4.922267,"median":-3.137242,"eighty":-0.969039,"marketCap":14113006},{"date":"2025-08-08","current":-8.476938,"twenty":-5.004125,"median":-3.155299,"eighty":-0.973817,"marketCap":13096869},{"date":"2025-08-15","current":-8.18463,"twenty":-5.134029,"median":-3.19779,"eighty":-0.976803,"marketCap":12645253},{"date":"2025-08-22","current":-7.746168,"twenty":-5.410414,"median":-3.21607,"eighty":-0.982233,"marketCap":11967829},{"date":"2025-08-29","current":-7.600014,"twenty":-5.856236,"median":-3.245278,"eighty":-0.987228,"marketCap":11742021},{"date":"2025-09-05","current":-7.819245,"twenty":-6.049761,"median":-3.325781,"eighty":-0.992223,"marketCap":12080733},{"date":"2025-09-12","current":-7.143282,"twenty":-6.209629,"median":-3.343916,"eighty":-1.006667,"marketCap":11036370},{"date":"2025-09-19","current":-10.354516,"twenty":-6.696876,"median":-3.375088,"eighty":-1.026648,"marketCap":11742021},{"date":"2025-09-26","current":-11.070023,"twenty":-7.035762,"median":-3.443585,"eighty":-1.030557,"marketCap":12553406},{"date":"2025-10-03","current":-11.383325,"twenty":-7.364852,"median":-3.487865,"eighty":-1.042883,"marketCap":12908691},{"date":"2025-10-10","current":-13.054272,"twenty":-7.512322,"median":-3.569805,"eighty":-1.058791,"marketCap":14803545},{"date":"2025-10-17","current":-11.174457,"twenty":-7.59231,"median":-3.644879,"eighty":-1.068565,"marketCap":12671834},{"date":"2025-10-24","current":-11.278891,"twenty":-7.731553,"median":-3.707687,"eighty":-1.123948,"marketCap":12790262},{"date":"2025-10-31","current":-10.75672,"twenty":-7.950784,"median":-3.905854,"eighty":-1.280758,"marketCap":12198121},{"date":"2025-11-07","current":-9.567215,"twenty":-8.038476,"median":-3.996712,"eighty":-1.310622,"marketCap":10849222},{"date":"2025-11-14","current":-8.045608,"twenty":-8.360015,"median":-4.312242,"eighty":-1.376104,"marketCap":9123720},{"date":"2025-11-21","current":-6.109399,"twenty":-8.170015,"median":-4.417419,"eighty":-1.474489,"marketCap":6928059},{"date":"2025-11-28","current":-5.587228,"twenty":-8.111553,"median":-4.501561,"eighty":-1.508371,"marketCap":6335917},{"date":"2025-12-05","current":-25.23826,"twenty":-8.403861,"median":-4.535397,"eighty":-1.515701,"marketCap":28620187},{"date":"2025-12-12","current":-21.591766,"twenty":-8.696169,"median":-4.627772,"eighty":-1.520317,"marketCap":24485063},{"date":"2025-12-19","current":-17.597159,"twenty":-9.06593,"median":-4.711914,"eighty":-1.541633,"marketCap":19955178},{"date":"2025-12-26","current":-13.245735,"twenty":-9.27961,"median":-4.754698,"eighty":-1.546299,"marketCap":15020663},{"date":"2026-01-02","current":-14.777436,"twenty":-10.201257,"median":-4.798393,"eighty":-1.579229,"marketCap":16757612},{"date":"2026-01-09","current":-23.341039,"twenty":-10.662157,"median":-4.922267,"eighty":-1.630419,"marketCap":26468738},{"date":"2026-01-16","current":-21.842963,"twenty":-11.038692,"median":-4.999213,"eighty":-1.702674,"marketCap":24769920},{"date":"2026-01-23","current":-22.02569,"twenty":-11.165081,"median":-5.003554,"eighty":-1.780942,"marketCap":24977133},{"date":"2026-01-30","current":-18.441421,"twenty":-11.278891,"median":-5.035187,"eighty":-1.871075,"marketCap":20912571},{"date":"2026-02-06","current":-17.471559,"twenty":-11.383325,"median":-5.167341,"eighty":-1.959036,"marketCap":19812748},{"date":"2026-02-13","current":-19.664289,"twenty":-11.445985,"median":-5.322255,"eighty":-2.161828,"marketCap":22299304},{"date":"2026-02-20","current":-19.158274,"twenty":-11.780175,"median":-5.500199,"eighty":-2.356399,"marketCap":21725483},{"date":"2026-02-27","current":-19.24261,"twenty":-12.048622,"median":-5.587228,"eighty":-2.377712,"marketCap":21821120},{"date":"2026-03-06","current":-19.130163,"twenty":-12.337157,"median":-5.805751,"eighty":-2.404957,"marketCap":21693605},{"date":"2026-03-13","current":-21.491564,"twenty":-13.089202,"median":-5.977481,"eighty":-2.428961,"marketCap":24371434},{"date":"2026-03-20","current":-18.975548,"twenty":-13.87234,"median":-6.068669,"eighty":-2.429444,"marketCap":21518271},{"date":"2026-03-27","current":-6.571741,"twenty":-14.681705,"median":-6.104823,"eighty":-2.432754,"marketCap":21916757},{"date":"2026-04-02","current":-6.133576,"twenty":-14.29878,"median":-6.093857,"eighty":-2.438272,"marketCap":20455475},{"date":"2026-04-10","current":-5.228861,"twenty":-14.168236,"median":-6.058175,"eighty":-2.459999,"marketCap":17438252},{"date":"2026-04-17","current":-5.848317,"twenty":-13.976774,"median":-5.969011,"eighty":-2.460689,"marketCap":19504138},{"date":"2026-04-24","current":-7.906455,"twenty":-13.454603,"median":-6.058175,"eighty":-2.469311,"marketCap":26368026},{"date":"2026-05-01","current":-8.924253,"twenty":-13.245735,"median":-6.093519,"eighty":-2.483106,"marketCap":29762383},{"date":"2026-05-08","current":-7.936411,"twenty":-13.245735,"median":-6.109399,"eighty":-2.496901,"marketCap":26467930},{"date":"2026-05-15","current":-8.430332,"twenty":-13.097935,"median":-6.18242,"eighty":-2.517594,"marketCap":28115156},{"date":"2026-05-22","current":-7.100113,"twenty":-13.054272,"median":-6.295839,"eighty":-2.548287,"marketCap":23678877},{"date":"2026-05-29","current":-9.261017,"twenty":-12.817554,"median":-6.483666,"eighty":-2.548563,"marketCap":30885492},{"date":"2026-06-05","current":-7.184304,"twenty":-12.577356,"median":-6.653598,"eighty":-2.591548,"marketCap":23959654},{"date":"2026-06-12","current":-6.49955,"twenty":-12.378931,"median":-6.640969,"eighty":-2.628587,"marketCap":21675999},{"date":"2026-06-18","current":-7.425652,"twenty":-12.330195,"median":-6.571741,"eighty":-2.650742,"marketCap":24764549},{"date":"2026-06-26","current":-6.409746,"twenty":-12.260573,"median":-6.632,"eighty":-2.70965,"marketCap":21376504},{"date":"2026-07-02","current":-7.116951,"twenty":-12.177025,"median":-6.653598,"eighty":-2.796579,"marketCap":23735032},{"date":"2026-07-10","current":-8.059891,"twenty":-12.10238,"median":-6.750178,"eighty":-2.921331,"marketCap":26879737},{"date":"2026-07-17","current":-7.296559,"twenty":-12.01284,"median":-7.006752,"eighty":-2.995391,"marketCap":24334024},{"date":"2026-07-24","current":-8.593101,"twenty":-11.905496,"median":-7.027147,"eighty":-3.017632,"marketCap":28657992},{"date":"2026-07-31","current":-6.522001,"twenty":-11.884609,"median":-7.027147,"eighty":-3.030526,"marketCap":21750873},{"date":"2026-08-07","current":-6.449035,"twenty":-11.801062,"median":-6.876942,"eighty":-3.037515,"marketCap":21507533},{"date":"2026-08-14","current":-6.033693,"twenty":-11.780175,"median":-6.701609,"eighty":-3.042447,"marketCap":20122366},{"date":"2026-08-21","current":-5.887762,"twenty":-11.696628,"median":-6.632,"eighty":-3.047315,"marketCap":19635685}],"updateTime":1787510289087},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624530526","title":"Polyrizon director Carmel Liron disposes of shares worth $0.0011 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530526","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530526?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:25","pubTimestamp":1774988712,"startTime":"0","endTime":"0","summary":"Polyrizon director Carmel Liron sold 100 ordinary shares on March 30, 2026.Holdings fell to 4,069 ordinary shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL8FLtNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624530534","title":"Polyrizon CEO Tomer Izraeli disposes of 3,900 shares worth $0.04 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530534","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530534?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:24","pubTimestamp":1774988647,"startTime":"0","endTime":"0","summary":"Polyrizon CEO Tomer Izraeli sold 3,900 ordinary shares on March 30, 2026 at USD 10.9 per share.Izraeli reported beneficial ownership of 32,012 ordinary shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL39DCCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Polyrizon CEO Tomer Izraeli disposes of 3,900 shares worth $0.04 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622543863","title":"Polyrizon completes FDA pre-submission meeting for NASARIX; submits FDA Pre-RFD for PL-16 viral blocker","url":"https://stock-news.laohu8.com/highlight/detail?id=2622543863","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622543863?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:23","pubTimestamp":1774531400,"startTime":"0","endTime":"0","summary":"Polyrizon completed an FDA pre-submission meeting for its PL-14  allergy blocker to discuss clinical development strategy and potential human trials.The company submitted a pre-request for designation to the FDA for its PL-16 viral blocker.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL6ZtQKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014005.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BKPKM429.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","BK4588","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","NDAQ","PLRZ","IE00BN0W2V16.EUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622888190","title":"Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2622888190","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622888190?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:25","pubTimestamp":1774473900,"startTime":"0","endTime":"0","summary":"Raanana, Israel, March  25, 2026 (GLOBE NEWSWIRE) --  Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solution","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262640/0/en/Polyrizon-Ltd-Files-Annual-Report-on-Form-20-F-for-the-Fiscal-Year-Ended-December-31-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622746007","title":"Polyrizon FY2025 operating loss widened 380% to $6.25 million; revenue was no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2622746007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622746007?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:24","pubTimestamp":1774473863,"startTime":"0","endTime":"0","summary":"Polyrizon published its annual report  with FY 2025 results, reporting no revenue and a net loss and comprehensive loss of USD 3.3 million.Research and development expenses were USD 2.1 million, with the increase attributed mainly to higher activity following its IPO completed at the end of 2024.General and administrative expenses were USD 4.1 million, driven primarily by increased activity following the IPO and including a USD 464,000 business email compromise theft loss recorded in Q4 2025.Financing income, net was USD 2.9 million, mainly due to a higher fair value revaluation of derivative warrant liability tied to the March 2025 private placement.Cash and cash equivalents totaled USD 1.3 million and bank deposits were USD 16.2 million as of Dec. 31, 2025, and management said it expects its cash and cash equivalents to fund operations through March 2030.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL6rgZTS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062014","title":"Polyrizon signs MOU to buy up to 20% of Colugo for up to USD 6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062014","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062014?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:47","pubTimestamp":1774356435,"startTime":"0","endTime":"0","summary":"Polyrizon signed a non-binding MOU with shareholders of Colugo to acquire up to a 20% stake in the company.The aggregate purchase price is up to USD 6.0 million, payable in cash or via issuance of Polyrizon shares.Two Colugo shareholders would sell approximately 20% of Colugo’s fully diluted share capital to Polyrizon.The transaction is expected to close within 7 days after conditions are met, including a definitive agreement and corporate approvals.The MOU terminates upon written notice by either party or on September 30, 2026 if the transaction has not closed.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8bMndj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","PLRZ","BK4112","NDAQ","LU2095319765.USD","LU0314104364.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4585","SG9999014013.SGD","LU2210149790.SGD","BK4588","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062099","title":"Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced Evtol Drones for Defense and Urban Air Mobility Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062099?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:47","pubTimestamp":1774356420,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUA31CH51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620324472","title":"Polyrizon Ltd. Director Liat Sidi Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620324472","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620324472?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:45","pubTimestamp":1773830713,"startTime":"0","endTime":"0","summary":"Polyrizon director Liat Sidi filed an initial statement of beneficial ownership on 03/18/2026. The filing reported direct beneficial ownership of 3,648 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5bjDbT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232102","title":"Polyrizon Ltd. Chief Science Officer Eyal S. Ron filed initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232102","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232102?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:44","pubTimestamp":1773830673,"startTime":"0","endTime":"0","summary":"Polyrizon reported an initial statement of beneficial ownership by Eyal Ron, Chief Science Officer. Ron reported direct beneficial ownership of 1,459 ordinary shares. Ron also reported options to purchase 8 ordinary shares at a USD 1,018.3 exercise price. He additionally reported options to purchase 10 ordinary shares at a USD 1,699.3 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7vngbZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620192232","title":"Polyrizon Ltd. Director Yehonatan Zalman Vinokur Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620192232","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620192232?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:43","pubTimestamp":1773830591,"startTime":"0","endTime":"0","summary":"Polyrizon director Yehonatan Zalman Vinokur filed an Initial Statement of Beneficial Ownership on March 18, 2026. The filing reported 2 ordinary shares held directly. It also reported 3,646 ordinary shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4zn4TN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620823218","title":"Polyrizon Ltd. files Form 3 initial beneficial ownership statement for Director Carmel Liron","url":"https://stock-news.laohu8.com/highlight/detail?id=2620823218","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620823218?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:42","pubTimestamp":1773830536,"startTime":"0","endTime":"0","summary":"Polyrizon reported an initial statement of beneficial ownership filed by director Carmel Liron. The filing listed 2 ordinary shares beneficially owned directly. It also reported 4,167 ordinary shares beneficially owned directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9P2M6l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232187","title":"Polyrizon Ltd. files initial beneficial ownership statement for CTO Tidhar Turgeman","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232187","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232187?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:41","pubTimestamp":1773830480,"startTime":"0","endTime":"0","summary":"Tidhar Turgeman, Chief Technology Officer of Polyrizon, filed an initial statement of beneficial ownership dated 03/18/2026. He reported direct beneficial ownership of 18 ordinary shares. He also reported direct beneficial ownership of 20,417 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLJjXnk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620617232","title":"Polyrizon Ltd. director Oz Adler files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620617232","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620617232?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:40","pubTimestamp":1773830407,"startTime":"0","endTime":"0","summary":"Oz Adler, a director at Polyrizon, filed an initial statement of beneficial ownership dated 03/18/2026. The filing reported direct beneficial ownership of 100 ordinary shares. It also reported direct beneficial ownership of 23,042 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3JKYqB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232668","title":"Polyrizon Ltd. files Form 3 beneficial ownership statement for CEO Tomer Izraeli","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232668","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232668?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:39","pubTimestamp":1773830349,"startTime":"0","endTime":"0","summary":"Polyrizon reported an initial statement of beneficial ownership by Tomer Izraeli, its chief executive officer and a director. Izraeli reported direct beneficial ownership of 35,912 ordinary shares. Izraeli also reported options to purchase 88 ordinary shares at exercise prices of USD 1,699.3 and USD 1,700.3.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3ZVdMJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620545232","title":"Polyrizon Ltd. CFO Nir BenYosef files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620545232","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620545232?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:38","pubTimestamp":1773830290,"startTime":"0","endTime":"0","summary":"Polyrizon reported an initial statement of beneficial ownership for Nir BenYosef, its Chief Financial Officer. The filing shows BenYosef beneficially owned 732 ordinary shares directly. It also lists a direct option to purchase 2 ordinary shares with an exercise price of USD 1,699.3.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL1z1lc5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620983422","title":"Polyrizon signs agreement with research organization for clinical development","url":"https://stock-news.laohu8.com/highlight/detail?id=2620983422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620983422?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:35","pubTimestamp":1773750948,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) signed an agreement with a global preclinical Contract Research Organization, or CRO, an expert in biocompatibility and regulatory...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-signs-agreement-with-research-organization-for-clinical-development-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-signs-agreement-with-research-organization-for-clinical-development-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424201","title":"Polyrizon signs agreement with global preclinical CRO for ISO 10993 biocompatibility studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424201","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424201?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:25","pubTimestamp":1773750341,"startTime":"0","endTime":"0","summary":"Polyrizon signed an agreement with a global preclinical contract research organization to run biocompatibility studies under ISO 10993 and GLP requirements. The studies are expected to begin in Q2 2026 and include cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity, and pyrogenicity assessments. CEO Tomer Izraeli said the work is intended to support regulatory submissions ahead of planned clinical trials later in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL1yjTww:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4588","BK4139","IE00BN0W2T93.GBP","NDAQ","PLRZ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014005.SGD","BK4112","BK4585","LU0314104364.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620242274","title":"Polyrizon Signs an Agreement With Leading Global Preclinical Cro as Part of Clinical Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2620242274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620242274?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:25","pubTimestamp":1773750300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA43MW7V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618937100","title":"Polyrizon Produces GMP Clinical Trial Material Batch With Eurofins CDMO AmatsiAquitaine","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937100","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937100?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:55","pubTimestamp":1773143757,"startTime":"0","endTime":"0","summary":"Polyrizon said it successfully produced a Good Manufacturing Practice  batch of clinical trial material for its lead intranasal product candidate. The batch was manufactured with Eurofins CDMO AmatsiAquitaine and is intended to support a planned U.S. clinical study later this year. Polyrizon said the GMP batch followed two prior development batches that showed batch-to-batch consistency and product stability over time.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL6NFH0m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","BK4139","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","PLRZ","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD","SG9999014039.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618937903","title":"Polyrizon Announces Gmp Manufacturing of Clinical Trial Material (Ctm) With Eurofins CDMO Amatsiaquitaine S.a.s for Planned U.S. Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937903?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:55","pubTimestamp":1773143700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA5MXWMW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":63,"code":"91000000","status":"200"}]}}